The latest imported new diabetes drugs are mainly divided into four categories: DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and imported insulin. 1. DPP-4 inhibitors, including selegiline and alogliptin, inhibit the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), increase the levels of endogenous GLP-1 and GIP, and promote the release of insulin from pancreatic islet β-cells to lower blood glucose levels. 2. SGLT-2 inhibitors, including dagliflozin and cagliflozin, etc., mainly inhibit glucose reabsorption in the kidney, prompting patients to excrete excess glucose in the urine, and then effectively reduce blood glucose levels. 3. GLP-1 receptor agonists, including liraglutide and exenatide, agonize glucagon-like peptide-1 receptor, play the role of intestinal insulin and produce glucose-lowering effect, which is a class of insulin secretion drugs that can lower blood glucose as well as body weight, and they also show advantages in cardiovascular protection. 4. Imported insulin includes Dieter’s insulin, Glycine insulin, Degu insulin, etc. The production process is more mature and stable. It is recommended that patients consult professional doctors in regular hospitals and use medication reasonably under their guidance.